There is growing evidence suggesting that antagonists of group II metabotropic glutamate
receptors (mGluR2/3) exhibit antidepressant-like properties in several preclinical models of …

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist showing selectivity to
mGluR2/3 but having measurable antagonist efficacy across all mGluR subtypes at 10–1000 …

Numerous studies over the last few years have suggested that modulating the glutamatergic
system may be an efficient method to achieve an antidepressant effect. Data suggest that …

Glutamatergic neurotransmission has been strongly implicated in the pathophysiology of
affective disorders, such as major depression and anxiety. Of all glutamate receptors, the …

The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …

Antidepressant-like effects of metabotropic glutamate (mGlu) 5 receptor antagonists have
been reported previously. We now provide definitive identification of mGlu5 receptors as a …

Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset
that can prolong distress and impairment for patients, and realworld effectiveness trials …

Previous preclinical work has demonstrated the therapeutic potential of antagonists of the
group II metabotropic glutamate receptors (mGlus). Still, compounds that are selective for the …

There is increasing evidence suggesting a role of the neurotransmitter glutamate in
depression. The metabotropic glutamate (mGlu) receptors are G-protein coupled receptors …

Phenotypic studies of mice lacking metabotropic glutamate receptor subtype 7 (mGluR7)
suggest that antagonists of this receptor may be promising for the treatment of central …